Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Combined With Azacitidine as Maintenance Therapy After Allo-HSCT for NK/T-cell Lymphoma
NCT07276698Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of selinexor in Natural killer T-cell lymphoma (NKTL), sponsored by Shanghai General Hospital. Primary endpoints: Progression-Free Survival at 2 years and Overall Survival at 2 years. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT07276698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276698.